cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   35 News 
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer
    Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC) (M) -  Jul 27, 2023 - Abstract #ESMO2023ESMO_975;    
    P1, P1b
    CI, confidence intervals; CBR, clinical benefit rate; CR, complete response; EGFR, epidermal growth factor; mDOR, median duration of response; mPFS, median progression free survival; NSQ, nonsquamous; ORR, objective response rate; PR, partial response; PTK7, protein tyrosine kinase 7; pts, patients; SD, stable disease; WT, wild type. Conclusions Cofe-P was well-tolerated with encouraging antitumor activity observed in rNSCLC and 30% ORR in the subpopulation with NSQ EGFR WT NSCLC and PTK7 ?90%/?2+.
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    Journal:  MTX-13, a novel PTK7-directed antibody-drug conjugate with widened therapeutic index shows sustained tumor regressions for a broader spectrum of PTK7-positive tumors. (Pubmed Central) -  Jun 23, 2023   
    When using a potent microtubule inhibitor (Aur0101), PTK7-targeting antibody-drug conjugate (ADC), h6M24-vc0101 (PF-06647020/Cofetuzumab pelidotin) is efficacious only in limited tumor types with low response rates in a phase I trial...MTX-13 displayed a favorable pharmacokinetic and safety profile in monkey with a highest non-severely toxic dose (HNSTD) of >30 mg/kg, significantly higher than 3-5 mg/kg of HNSTD for h6M24-vc0101. The higher therapeutic index of MTX-13 bodes well for its clinical translation with a potential to expand responding patient population beyond that of current PTK7-targeting ADCs.
  • ||||||||||  prexasertib (ACR-368) / Acrivon Therap, cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie, GSK461364 / GSK
    Journal:  Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention. (Pubmed Central) -  Aug 22, 2022   
    Furthermore, using high-throughput drug sensitivity testing (525 drugs) we show that targeting PTK7 exhibited synergistic activity with chemotherapeutic agent paclitaxel, CHK1/2 inhibitor prexasertib, and PLK1 inhibitor GSK461364, among others, in OC cells and ex vivo primary samples. Taken together, our study provides unique insight into the function of PTK7, which helps to define its role in mediating aberrant Wnt signaling in ovarian cancer.
  • ||||||||||  PF-06650808 / Pfizer, PF-06664178 / Pfizer, cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    PK/PD data, Journal:  Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody-Drug Conjugates. (Pubmed Central) -  Jun 19, 2022   
    For instance, the linker stability estimates for PF-06650808, PF-06647020, and PF-06664178 were 0.31, 0.14, and 0.096, respectively, from the JDM-based analyses vs. 0.23, 0.11, and 0.086 by the model-based approach. Additionally, the JDMs were estimated for a number of FDA-approved or otherwise well-documented ADCs, showing their utilities in comparing ADCs in terms of favorable PK characteristics.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic. (Pubmed Central) -  Mar 11, 2022   
    In this work, all these active targeted nanomedicines are discussed, analyzing their advantages and disadvantages over conventional chemotherapy as well as the challenges involved in their lab to clinical translation. In addition, examples of formulations developed and evaluated at the preclinical level are also discussed.
  • ||||||||||  gedatolisib (PF-05212384) / Celcuity
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer (clinicaltrials.gov) -  Jan 7, 2021   
    P1,  N=18, Completed, 
    The study commenced on February 13, 2020 and enrollment is ongoing. Recruiting --> Completed | Trial completion date: Jun 2021 --> May 2020 | Trial primary completion date: Jan 2021 --> May 2020
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors (Virtual Meeting II: E-Posters) -  May 16, 2020 - Abstract #AACRII2020AACR-II_905;    
    PTK7 therefore appears to be an attractive target for solid cancer therapeutic intervention and has been targeted clinically with an Antibody Drug Conjugate (PF-06647020)...Latent toxicity that was more variable amongst the xenograft experiments was also observed. Understanding and developing appropriate mitigation strategies to address the observed toxicities may be required to develop further a safe and efficacious allogeneic anti-PTK7 CAR-T cell therapy for solid tumor cancers.
  • ||||||||||  gedatolisib (PF-05212384) / Celcuity
    Trial completion date, Trial primary completion date, Metastases:  An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer (clinicaltrials.gov) -  Feb 17, 2020   
    P1,  N=18, Recruiting, 
    Understanding and developing appropriate mitigation strategies to address the observed toxicities may be required to develop further a safe and efficacious allogeneic anti-PTK7 CAR-T cell therapy for solid tumor cancers. Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jan 2020 --> Jan 2021
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    Enrollment closed, Metastases:  A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 19, 2019   
    P1,  N=138, Active, not recruiting, 
    Trial completion date: Jan 2020 --> Jun 2020 | Trial primary completion date: Aug 2019 --> Jan 2020 Recruiting --> Active, not recruiting
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    Trial completion date, Trial primary completion date, Metastases:  A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Dec 26, 2018   
    P1,  N=190, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Apr 2020 --> Apr 2019 | Trial primary completion date: Apr 2020 --> Apr 2019
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    Trial completion date, Trial primary completion date, Metastases:  A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Aug 27, 2018   
    P1,  N=190, Recruiting, 
    Trial completion date: Apr 2020 --> Apr 2019 | Trial primary completion date: Apr 2020 --> Apr 2019 Trial completion date: Nov 2019 --> Mar 2020 | Trial primary completion date: Nov 2019 --> Mar 2020
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    Trial completion date, Trial primary completion date, Metastases:  A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 15, 2018   
    P1,  N=190, Recruiting, 
    Trial completion date: Nov 2019 --> Mar 2020 | Trial primary completion date: Nov 2019 --> Mar 2020 Trial completion date: Jul 2019 --> Nov 2019 | Trial primary completion date: Jul 2019 --> Nov 2019
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    Enrollment open, Enrollment change, Metastases:  A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Aug 15, 2017   
    P1,  N=190, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Jan 2018 Active, not recruiting --> Recruiting | N=112 --> 190
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    Enrollment change, Trial primary completion date, Metastases:  A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jun 9, 2017   
    P1,  N=190, Active, not recruiting, 
    N=190 --> 112 N=150 --> 190 | Trial primary completion date: Jul 2017 --> Jul 2019
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    Enrollment closed, Metastases:  A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 11, 2017   
    P1,  N=150, Active, not recruiting, 
    N=150 --> 190 | Trial primary completion date: Jul 2017 --> Jul 2019 Suspended --> Active, not recruiting
  • ||||||||||  cofetuzumab pelidotin (ABBV-647) / Pfizer, AbbVie
    Enrollment closed, Metastases:  A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 15, 2017   
    P1,  N=150, Active, not recruiting, 
    Active, not recruiting --> Suspended Recruiting --> Active, not recruiting